Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, has announced its participation in three upcoming investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference (September 3), the H.C. Wainwright Global Investment Conference (September 9), and the Stifel Virtual Immunology and Inflammation Forum (September 15). All presentations will be available via webcast on the company's investor relations website, with replays accessible for at least 30 days.
Avalo Therapeutics (NASDAQ: AVTX), azienda biotech in fase clinica specializzata in terapie basate su IL-1β per malattie infiammatorie a mediazione immunitaria, ha annunciato la partecipazione a tre conferenze per investitori previste a settembre 2025.
La società presenterà al Cantor Global Healthcare Conference (3 settembre), al H.C. Wainwright Global Investment Conference (9 settembre) e al Stifel Virtual Immunology and Inflammation Forum (15 settembre). Tutte le presentazioni saranno trasmesse via webcast sul sito investor relations dell’azienda e le registrazioni saranno disponibili in replay per almeno 30 giorni.
Avalo Therapeutics (NASDAQ: AVTX), empresa biotecnológica en fase clínica centrada en tratamientos basados en IL-1β para enfermedades inflamatorias mediadas por el sistema inmunitario, ha anunciado su participación en tres conferencias para inversores en septiembre de 2025.
La compañía presentará en la Cantor Global Healthcare Conference (3 de septiembre), en la H.C. Wainwright Global Investment Conference (9 de septiembre) y en el Stifel Virtual Immunology and Inflammation Forum (15 de septiembre). Todas las presentaciones se emitirán por webcast en la web de relaciones con inversores de la compañía y las repeticiones estarán disponibles al menos 30 días.
Avalo Therapeutics (NASDAQ: AVTX)는 면역 매개 염증 질환을 위한 IL-1β 기반 치료법을 개발하는 임상 단계 바이오텍 회사로, 2025년 9월에 열리는 세 건의 투자자 콘퍼런스에 참여한다고 발표했습니다.
회사는 Cantor Global Healthcare Conference(9월 3일), H.C. Wainwright Global Investment Conference(9월 9일), Stifel Virtual Immunology and Inflammation Forum(9월 15일)에서 발표할 예정입니다. 모든 발표는 회사의 투자자 관계 웹사이트를 통해 웨비캐스트로 제공되며, 재시청은 최소 30일간 가능할 것입니다.
Avalo Therapeutics (NASDAQ: AVTX), société biotechnologique en phase clinique spécialisée dans les traitements à base d’IL‑1β pour les maladies inflammatoires à médiation immunitaire, a annoncé sa participation à trois conférences investisseurs en septembre 2025.
La société présentera lors de la Cantor Global Healthcare Conference (3 septembre), de la H.C. Wainwright Global Investment Conference (9 septembre) et du Stifel Virtual Immunology and Inflammation Forum (15 septembre). Toutes les présentations seront diffusées en webcast sur le site relations investisseurs de la société, avec des replays disponibles pendant au moins 30 jours.
Avalo Therapeutics (NASDAQ: AVTX), ein Biotech-Unternehmen in klinischer Phase, das sich auf IL‑1β-basierte Therapien für immunvermittelte Entzündungserkrankungen spezialisiert hat, hat seine Teilnahme an drei Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird auf der Cantor Global Healthcare Conference (3. September), der H.C. Wainwright Global Investment Conference (9. September) und dem Stifel Virtual Immunology and Inflammation Forum (15. September) präsentieren. Alle Präsentationen werden per Webcast auf der Investor‑Relations‑Website des Unternehmens verfügbar sein; Wiederholungen stehen für mindestens 30 Tage bereit.
- None.
- None.
WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:
Cantor Global Healthcare Conference
Fireside Chat
September 3, 2025, at 2:10 pm ET
H.C.Wainwright 27th Annual Global Investment Conference
Presentation
September 9, 2025, at 2:30 pm ET
Stifel 2025 Virtual Immunology and Inflammation Forum
Fireside Chat
September 15, 2025, at 11:00 am ET
Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit www.avalotx.com.
About AVTX-009
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases.1 It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-α, and IL-17. Dysregulated IL-1β signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1β inhibition has proven effective in multiple immune mediated inflammatory diseases.1-3
References: 1Dinarello CA. Immunol Rev. 2018;281(1):8-27. 2Kany S et al. Int J Mol Sci. 2019;20(23):6008. 3Kimball AB et al. Presented at: American Academy of Dermatology; March 8-12, 2024; San Diego, CA.
For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
or
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
FAQ
When is Avalo Therapeutics (AVTX) presenting at the Cantor Global Healthcare Conference 2025?
What type of company is Avalo Therapeutics (AVTX)?
Where can investors watch Avalo Therapeutics' (AVTX) conference presentations?
Which investor conferences will Avalo Therapeutics (AVTX) attend in September 2025?
